Search Patents
  • ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
    Publication number: 20230279080
    Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that is specific for a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
    Type: Application
    Filed: December 27, 2022
    Publication date: September 7, 2023
    Inventors: Kuo-I LIN, Chi-Huey WONG, Szu-Wen WANG, Yi-Hsuan CHANG
  • Mutant spike protein extending the tissue tropism of infectious bronchitis virus (IBV)
    Patent number: 9969777
    Abstract: The present invention provides an infectious bronchitis virus (IBV) spike protein (S protein) which is based on an S protein from an IBV strain with restricted tissue tropism, but which comprises the sequence XBBXBX in the part of the S2 protein corresponding to residues 686 to 691 of the sequence given as SEQ ID No. 2, where B is a basic residue and X is any amino acid; and which comprises at least one of the following amino acid substitutions with reference to the position numbering of SEQ ID NO:2: Leucine (L) to Phenylalanine (F) at position 578 Asparagine (N) to Serine (S) at position 617 Asparagine (N) to Serine (S) at position 826 Leucine (L) to Phenylalanine (F) at position 857 and Isoleucine (I) to Valine (V) at position 1000 such that an IBV virus comprising the S protein has extended tissue tropism. The present invention also provides a virus comprising such an S protein.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: May 15, 2018
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Paul Britton, Erica Bickerton
  • MONOCLONAL ANITBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS AND USE THEREOF
    Publication number: 20210355193
    Abstract: The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the Si domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
    Type: Application
    Filed: August 23, 2018
    Publication date: November 18, 2021
    Inventors: Hansaem Lee, Janghoon Choi, Sungsoon Kim, Lingshu Wang, Barney Graham, John Mascola
  • Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
    Patent number: 7491489
    Abstract: The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: February 17, 2009
    Assignee: The University of Hong Knog
    Inventors: Bojian Zheng, Yi Guan, Jiandong Huang, Ming-Liang He
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20230338508
    Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
    Type: Application
    Filed: March 10, 2021
    Publication date: October 26, 2023
    Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20230086390
    Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
    Type: Application
    Filed: March 10, 2021
    Publication date: March 23, 2023
    Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
  • ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
    Publication number: 20230105209
    Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
    Type: Application
    Filed: October 3, 2022
    Publication date: April 6, 2023
    Inventors: Kuo-I LIN, Che MA, Chi-Huey WONG, Szu-Wen WANG, Yi-Hsuan CHANG, Xiaorui CHEN, Han-Yi HUANG
  • Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein
    Publication number: 20070190065
    Abstract: Nucleic acid molecules, polypeptides, immunogenic compositions, vaccines, and methods of making and using the nucleotides and encoded polypeptides associated with the Spike protein of SARS Corona Virus (SARS CoV) are disclosed.
    Type: Application
    Filed: December 4, 2006
    Publication date: August 16, 2007
    Inventors: Ralf Altmeyer, Beatrice Nal-Rogier, Cheman Chan, Francois Kien, Yiu Kam, Yu Siu, Kong Tse, Isabelle Staropoli, Jean-Claude Manuguerra
  • MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF
    Publication number: 20230265169
    Abstract: The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.
    Type: Application
    Filed: September 25, 2022
    Publication date: August 24, 2023
    Inventors: Hansaem Lee, Janghoon Choi, Sungsoon Kim, Lingshu Wang, Barney Graham, John R Mascola
  • SARS-COV-2 SPIKE PROTEIN ANTIBODIES
    Publication number: 20230115257
    Abstract: Embodiments include monoclonal antibodies (mAbs) that recognize SARS-Cov-2 spike protein. The mAbs are capable of distinguishing among variants of the virus. The present disclosure also provides a composition and methods of making and using such a composition for treating, preventing, and/or detecting SARS-CoV-2 infection.
    Type: Application
    Filed: May 17, 2022
    Publication date: April 13, 2023
    Inventors: Brian A. ZABEL, Dan LUO, Ling ZHANG, Vydehi KANNEGANTI, Joyce YU, Sophie YANG, Lequn ZHAO, Hua TU, Xiaomei GE
  • Anti COVID-19 Therapies targeting nucleocapsid and spike proteins
    Publication number: 20240075129
    Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
    Type: Application
    Filed: October 17, 2023
    Publication date: March 7, 2024
    Applicant: ImmunityBio, Inc.
    Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
  • Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated as a vaccine
    Patent number: 11406702
    Abstract: A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: August 9, 2022
    Inventor: David Gordon Bermudes
  • Antibody specific to spike protein of SARS-CoV-2 and uses thereof
    Patent number: 11866485
    Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: January 9, 2024
    Assignee: ACADEMIA SINICA
    Inventors: Kuo-I Lin, Che Ma, Chi-Huey Wong, Szu-Wen Wang, Yi-Hsuan Chang, Xiaorui Chen, Han-Yi Huang
  • Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
    Patent number: 10973908
    Abstract: A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 13, 2021
    Inventor: David Gordon Bermudes
  • RECOMBINANT SARS-COV-2 SPIKE PROTEIN SUBUNITS, EXPRESSION AND USES THEREOF
    Publication number: 20230312656
    Abstract: The present invention is directed to the expression and secretion recombinant SARS-CoV-2 spike protein subunits. Various subunits have been designed and expressed as secreted products into the culture medium of transformed insect cell lines. The design of subunits is focused on the production of products that provide the ability to induce focused immune responses without inducing immune enhancing responses. The expressed and purified products are suitable as vaccine candidates to protect against disease caused by SARS-CoV-2.
    Type: Application
    Filed: September 1, 2021
    Publication date: October 5, 2023
    Inventors: David E. Clements, James T. Senda, Jaime S. Horton
  • SARS CORONAVIRUS 2 DIAGNOSTIC KIT INCLUDING RECEPTOR AND ANTIBODY BINDING TO SARS CORONAVIRUS 2 SPIKE PROTEIN
    Publication number: 20230160895
    Abstract: Provided are a composition for detecting SARS coronavirus 2, a composition for diagnosing SARS coronavirus 2 infection, a method for detecting SARS coronavirus 2, and a SARS coronavirus 2 infection diagnostic kit, wherein a receptor and an antibody that binds to SARS coronavirus 2 spike protein are used in order to detect SARS coronavirus 2 (SARS-CoV-2) or diagnose SARS coronavirus 2 infection (COVID-19).
    Type: Application
    Filed: June 18, 2021
    Publication date: May 25, 2023
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Hong Gi KIM, Jonghwan LEE, Bum Tae KIM
  • CLEAVING PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220064266
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Application
    Filed: April 28, 2021
    Publication date: March 3, 2022
    Inventors: Yang Xiang, Yan Tan
  • Quantum Dot Conjugated Virus Spike Protein for Cell-Based Bio-Sensing Systems and Drug Screening
    Publication number: 20220034884
    Abstract: Quantum dots conjugated to SARS-CoV-2 Spike protein receptor binding domain (RBD) interact with gold nanoparticles bound to angiotensin converting enzyme 2 (ACE2) and thus undergo energy transfer. This energy transfer indicates RBD/ACE binding and can be used to assay for inhibitors thereof. Moreover, these labeled quantum dots were found to undergo endocytosis in cells expressing ACE2.
    Type: Application
    Filed: July 30, 2021
    Publication date: February 3, 2022
    Inventors: Eunkeu Oh, Kimihiro Susumu, Mason A. Wolak, Kirill Gorshkov
  • BINDING AGENTS TO PRE-FUSION STATE SARS-COV-2 SPIKE PROTEIN
    Publication number: 20210403537
    Abstract: Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
    Type: Application
    Filed: September 17, 2020
    Publication date: December 30, 2021
    Inventors: Yang Xiang, Yan Tan
  • RECOMBINANT VECTORS ENCODING CHIMERIC CORONAVIRUS SPIKE PROTEINS AND USE THEREOF
    Publication number: 20240000920
    Abstract: The present invention provides recombinant vectors encoding a chimeric coronavirus spike protein. The present invention further provides new immunogenic compositions and vaccines comprising these recombinant vectors. Methods of administering these immunogenic compositions and vaccines to animal subjects, including humans, felines, and avians, to protect them against coronaviruses also are included. Methods of making the immunogenic compositions and vaccines alone or in combinations with other protective agents are provided too.
    Type: Application
    Filed: November 11, 2021
    Publication date: January 4, 2024
    Applicant: Intervet Inc.
    Inventors: Martijn Alexander Langereis, Ad De Groof, Paul Vermeij, Berend Jan Bosch
Narrow Results

Filter by US Classification